Panel Discussion: Turning Setbacks into Strategy, what Clinical Trial Failures Teach us About Building Better Oligonucleotide Therapies

Time: 9:00 am
day: Conference Day One

Details:

• Unpack the reasons behind trial discontinuations: Was it the oligo, delivery system, or something else?
• Identify overlooked red flags in preclinical models, PK data, or target biology that led to setbacks
• Discuss how teams rebounded, what pivots, partnerships, or reformulations turned failure into future success

Speakers:

MARCIN KORTYLEWSKI Marcin Kortylewski, Ph.D. is a Professor in the Department of Immuno-Oncology at the Beckman Research Institute, City of Hope. His research focuses on the molecular Read more

David Guay David Guay is the Research Director at Feldan Therapeutics since 2009. Dr. Guay received his PhD in molecular and cell biology from Laval University for Read more

HAGEN Cramer Dr. Hagen Cramer is a renowned expert in all chemistry-related aspects of oligonucleotide therapeutic development. He has worked in the biotech industry for over 25 Read more